Sort
10,766 grants matching “checkpoint inhibitor”
Molecular Imaging Reagents for Prostate Cancer Theranostics
$240,484Zaver M Bhujwalla · Johns Hopkins University · P41 · FY2018 · EB
SPORE: Targeted Therapies for Glioma
$240,300Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2022 · CA
Molecular Imaging Reagents for Prostate Cancer Theranostics
$240,117Zaver M Bhujwalla · Johns Hopkins University · P41 · FY2017 · EB
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
$240,106Hyun-Sung Lee · Baylor College Of Medicine · R21 · FY2023 · AI
Core B: Biological Models, Multiplexed Optical Biopsy, Molecular Pathology, and Biostatistics Core
$240,059Bryan Quilty Spring · Massachusetts General Hospital · P01 · FY2022 · CA
STAT1: New regulator of inflammatory Th17 and Th2 cells
$240,000Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R21 · FY2016 · AI
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma
$240,000Rahul Anil Sheth · University Of Tx Md Anderson Can Ctr · R21 · FY2019 · EB
Core 3: Mouse GBM models and Imaging Core
$239,939E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2024 · CA
Functional study of C53 protein as a novel regulator of checkpoint kinases
$239,913Honglin Li · Lurie Children'S Hospital Of Chicago · R01 · FY2008 · GM
INTERACTION OF YEAST CHECKPOINT PROTEINS AS DRUG ASSAY
$239,531Emory University · R01 · FY2001 · CA
Tissue-based predictive biomarkers for Cabozantinib therapy in metastatic renal cell carcinoma
$239,504Sabina Signoretti · Brigham And Women'S Hospital · R21 · FY2021 · CA
STRUCTURAL STUDIES OF PHOSPHOINOSITIDE RELATED PROTEIN KINASES
$239,464Gerwald Jogl · Brown University · P20 · FY2009 · RR
Immuno-Phenotyping Core
$239,455Young J. Kim · Vanderbilt University Medical Center · P50 · FY2021 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
$239,392Shana O Kelley · Northwestern University · R01 · FY2025 · CA
Targeting of Master Signaling Molecule to Restore Functions of Exhausted HIV-specific CTLs
$239,250Dongfang Liu · Methodist Hospital Research Institute · R21 · FY2017 · AI
Test if antitumor T cells use a putative super-enhancer in the Il1rl2-Il1rl1 intergenic region to form "innate-like" responses to cytokines
$239,250Adam J Adler · University Of Connecticut Sch Of Med/Dnt · R21 · FY2019 · AI
Identification of genomic drivers of brain metastases in renal cell carcinoma
$239,041Priscilla Kaliopi Brastianos · Massachusetts General Hospital · R21 · FY2018 · CA
The Houston Center for Acquired Resistance Research (H-CARR)
$238,959Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2024 · CA
Research Project Pancreatic Cancer
$238,949David G Denardo · Washington University · U54 · FY2025 · CA
Project 3: Mechanisms of immunotherapy action
$238,779Marcia Haigis · Harvard Medical School · U54 · FY2022 · CA
A novel strategy to overcome drug resistance in cancer
$238,727Aimee L Edinger · University Of California-Irvine · R01 · FY2022 · CA
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers
$238,661John D Minna · Ut Southwestern Medical Center · P50 · FY2021 · CA
Advancing WRN as a synthetic lethal target for microsatellite unstable cancers
$238,634Edmond Chan · Columbia University Health Sciences · K08 · FY2023 · CA
Advancing WRN as a synthetic lethal target for microsatellite unstable cancers
$238,634Edmond Chan · Columbia University Health Sciences · K08 · FY2024 · CA
Advancing WRN as a synthetic lethal target for microsatellite unstable cancers
$238,634Edmond Chan · Columbia University Health Sciences · K08 · FY2022 · CA